Brokerages Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Target Price at $29.75

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have been given an average rating of “Moderate Buy” by the ten analysts that are currently covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $28.75.

A number of research firms have weighed in on JSPR. Royal Bank Of Canada downgraded Jasper Therapeutics from an “outperform” rating to a “sector perform” rating and set a $5.00 price objective on the stock. in a report on Tuesday, July 8th. UBS Group decreased their price target on Jasper Therapeutics from $29.00 to $25.00 and set a “buy” rating on the stock in a research note on Friday. Cantor Fitzgerald lowered Jasper Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, July 7th. BMO Capital Markets reissued a “market perform” rating on shares of Jasper Therapeutics in a report on Tuesday, July 8th. Finally, HC Wainwright lowered their target price on shares of Jasper Therapeutics from $40.00 to $20.00 and set a “buy” rating on the stock in a report on Monday, July 7th.

Jasper Therapeutics Price Performance

Shares of Jasper Therapeutics stock opened at $3.11 on Thursday. The firm has a market capitalization of $46.71 million, a PE ratio of -0.52 and a beta of 2.70. The company’s fifty day moving average price is $4.16 and its two-hundred day moving average price is $4.78. Jasper Therapeutics has a 52-week low of $2.27 and a 52-week high of $26.05.

Jasper Therapeutics (NASDAQ:JSPR) last issued its earnings results on Wednesday, August 13th. The company reported ($1.74) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.54). Analysts predict that Jasper Therapeutics will post -4.47 earnings per share for the current fiscal year.

Institutional Trading of Jasper Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Wells Fargo & Company MN grew its holdings in Jasper Therapeutics by 106.7% during the 4th quarter. Wells Fargo & Company MN now owns 7,415 shares of the company’s stock worth $159,000 after acquiring an additional 3,828 shares during the last quarter. Acadian Asset Management LLC bought a new position in Jasper Therapeutics in the 1st quarter worth approximately $46,000. Tema Etfs LLC acquired a new position in Jasper Therapeutics during the 4th quarter worth $266,000. Engineers Gate Manager LP bought a new position in Jasper Therapeutics in the 2nd quarter valued at $78,000. Finally, Barclays PLC boosted its position in Jasper Therapeutics by 13.6% in the 4th quarter. Barclays PLC now owns 18,334 shares of the company’s stock valued at $392,000 after buying an additional 2,188 shares during the last quarter. 79.85% of the stock is currently owned by institutional investors and hedge funds.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.